MP29-02 for the treatment of seasonal allergic rhinitis: a review of clinical pharmacology, efficacy and safety

Abstract

This review presents the pharmacology, clinical efficacy and safety of MP29-02 (Dymista®), a unique product for the treatment of allergic rhinitis. Allergic rhinitis is often thought of more as a nuisance than a meaningful medical condition, and the health impact of allergic rhinitis can easily be underestimated. As a result, allergic rhinitis can be undertreated, expectations for relief may not be met, and patients may be left dissatisfied and non-compliant with their medications. MP29-02 is the only currently available allergic rhinitis medication to provide potent early-phase histamine-receptor blocking and long-term anti-inflammatory effects in a single intranasal formulation and delivery system that represents an advance in the therapy of allergic rhinitis, in particular for patients with moderate-to-severe disease.

Keywords::

• allergic rhinitis
• azelastine hydrochloride
• clinical trials
• fluticasone propionate
• intranasal
• randomized

Financial & competing interests disclosure

WE Berger has received honoraria, consulted for and received research support from MEDA and Alcon; has consulted for and received speaker fees from Sunovian and TEVA; and has received speaker fees from and served as an advisor for Allergan. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

The author would like to thank W Wheeler for editorial assistance and critical review of the manuscript.

Key issues

• • Allergic rhinitis is a global health problem. As many as 500 million people worldwide are affected by allergic rhinitis and its prevalence in the USA is now estimated at 60–90 million individuals or nearly 30% of the population.

• • Despite available therapies, studies continue to identify an unmet need for treatments that provide adequate relief of allergic rhinitis symptoms and for interventions that improve health-related quality of life for these patients.

• • In the MP29-02 direct comparative clinical trials, MP29-02 demonstrated statistical superiority to both reformulated and commercially available azelastine and fluticasone propionate for improving nasal symptoms of allergic rhinitis.

• • In all of the studies, the incidence and types of adverse events were similar across the active treatment groups. MP29-02, as a single spray administered twice daily, provided greater clinical efficacy than the monotherapy comparators in these studies.